Clinical trials: Cushing Disease
Iatrogenic Cushing's Disease
Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition
Currently, 2-3% of the population of the United Kingdom and United States of America receive glucocorticoid therapy. Significant adverse effects are not confined to chronic use; recurrent short-course administration is associated…
- Trial name
- TICSI (NCT03111810)
- Testing
- AZD4017 and prednisolone
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pituitary ACTH Hypersecretion, Acromegaly
Vitamin D Metabolism in Patients With Endocrine Disorders
This prospective controlled interventional study aims to reveal the diversity of vitamin D metabolism in patients with certain endocrine disorders (Cushing's disease, acromegaly, primary hyperparathyroidism, diabetes mellitus…
- Conditions
- Pituitary ACTH Hypersecretion, Acromegaly, Diabetes Mellitus, Type 1, Primary Hyperparathyroidism
- Trial name
- NCT04844164
- Testing
- Cholecalciferol 15000 UNT/ML Oral Solution
- Where
- Russia
- Volunteers
- 261 people, healthy volunteers welcome
- Sponsor
- Endocrinology Research Centre, Moscow
Cushing Disease, Pituitary Adenoma
FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease
The purpose of this research is to evaluate the performance [sensitivity, specificity, accuracy] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
- Trial name
- NCT07460232
- Testing
- Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Cushing's Syndrome
Study of Depression, Peptides, and Steroids in Cushing's Syndrome
OBJECTIVES: I. Study the relationship between dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and disorders of mood, vegetative function, and cognition in patients with Cushing's disease. II.
- Trial name
- NCT00004334
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Center for Research Resources (NCRR)
Subclinical Hypercortisolism, Cushing Syndrome
Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism
Background: Adrenal tumors are a common kind of tumor. Some of these secrete extra cortisol into the body, which can lead to diabetes, obesity, and other diseases.
- Conditions
- Subclinical Hypercortisolism, Cushing Syndrome, Adrenal Neoplasm
- Trial name
- NCT02001051
- Testing
- Adrenalectomy, Observation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Cushing's Syndrome
Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
This study will investigate the potential for FK506 binding protein 5 (FKBP5) (and other gene expression markers, for example pentraxin 3 [PTX-3], serum/glucocorticoid regulated kinase 1 [SGK1], and glycogen synthase kinase 3…
- Trial name
- NCT02922257
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Corcept Therapeutics
Adrenal Tumor, Pheochromocytoma
Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy
Laparoscopic adrenalectomy has become the gold standard operation for non-malignant adrenal tumors replacing open adrenalectomy.
- Conditions
- Adrenal Tumor, Pheochromocytoma, Conn's Syndrome, Cushing's Syndrome
- Trial name
- NCT01959711
- Testing
- Posterior RA, Lateral transperitoneal LA
- Where
- Poland
- Volunteers
- 65 people
- Sponsor
- Jagiellonian University
Cushing Syndrome, Fatty Liver Disease
NAC- NAFLD And Cushing
Cushing's Syndrome is a rare disease resulting from prolonged exposure to high levels of circulating cortisol. Clinical manifestations are variable but many patients present a metabolic syndrome (abdominal obesity, insulin…
- Trial name
- NAC (NCT05881005)
- Testing
- hepatic MRI
- Where
- 7 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Adrenal Incidentalomas, Cushing Syndrome
Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome
Drug interventional, controlled, randomized open-label, parallel-group, multicenter study in patients with bilateral adrenal incidentalomas associated with subclinical Cushing's syndrome
- Trial name
- NCT06801249
- Testing
- Metarapone, Standardized antihypertensive therapy
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Cushing Syndrome, Primary Aldosteronism
Continuous Steroid Monitoring in Interstitial Fluid With Wearable and Nanoparticle-enhanced Biosensors for Improved Management of Adrenal Disorders
The goal of this project is to provide novel technology that will pave the way from the present single-point (analogue) endocrinology towards continuous cortisol and aldosterone monitoring with full time resolution.
- Conditions
- Cushing Syndrome, Primary Aldosteronism, Adrenal Insufficiency
- Trial name
- NCT06980753
- Testing
- Participants will use the biossensor for 48 h
- Where
- Brazil
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Cushing Syndrome Related to Cortisolic Adenoma
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome
The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the…
- Trial name
- LIPOCUSH (NCT01688349)
- Testing
- analyze the role of glucocorticoid in AT distribution.
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Cushing Syndrome
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
Background: Cushing syndrome (CS) is a set of diseases that develop when the body produces too much adrenocorticotropic hormone (ACTH). ACTH stimulates the production of a hormone called cortisol.
- Trial name
- NCT06635629
- Testing
- Desmopressin, Dexamethasone
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cushing's Syndrome, Pituitary Adenoma
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
Lentiginosis refers to groups of diseases marked by the presence of pigmented spots on the skin. These conditions are most commonly associated with multiple tumors and changes in hormone producing glands.
- Conditions
- Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease
- Trial name
- NCT00001452
- Testing
- oCRH
- Where
- United States
- Volunteers
- 1,387 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Panhypopituitarism, Gigantism/Acromegaly
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood.
- Conditions
- Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
- Trial name
- NCT00001595
- Testing
- Tissue specimen collection, MRI
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing's Disease, Hypercortisolism
Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection
Cushing's disease is a rare condition where the body produces too much of a hormone called cortisol. Cortisol helps with metabolism, the immune system, and managing stress.
- Conditions
- Cushing's Disease, Hypercortisolism, Pituitary Adenoma, Pituitary ACTH Secreting Adenoma
- Trial name
- OPTIMAL (NCT06701838)
- Testing
- 11C-Methionine PET/CT
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Cushing Disease
Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms
Automated immunodosage methods (Roche Elecsys cortisol and IDS cortisol dosing kits) offer a simple and inexpensive technology routinely used in a medical biology laboratory.
- Trial name
- COSHING (NCT03974789)
- Testing
- Blood test, 24-hour Urine test, Saliva swab
- Where
- France
- Volunteers
- 380 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Adrenal Disease
Comparison Between Posterior Retroperitoneoscopic Adrenalectomy and Laparoscopic Adrenalectomy
The purpose of this study is to compare two surgical methods of adrenalectomy. One is called PRA(posterior retroperitoneal adrenalectomy), which is performed through 3 or 4 holes at patient's back.
- Trial name
- PRA (NCT01676025)
- Testing
- PRA, LA
- Where
- South Korea
- Volunteers
- 83 people
- Sponsor
- Seoul National University Hospital
Cushing's Syndrome
Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome
The purpose of this prospective, international phase III/IV study is to assess the efficacy and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks of treatment.
- Trial name
- PROMPT (NCT02297945)
- Testing
- metyrapone
- Where
- 36 sites in Belgium, Germany and 6 more
- Volunteers
- 50 people
- Sponsor
- HRA Pharma
Cushing Disease
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4 weeks of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing disease.
- Trial name
- NCT03774446
- Testing
- Seliciclib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Cedars-Sinai Medical Center